{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:48:28Z","timestamp":1787240908139,"version":"build-2736575974"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>BCMA-directed CAR T-cell therapies have improved outcomes in relapsed and refractory multiple myeloma (MM); however, the majority of patients relapse within 1 to 3 years following treatment. Managing disease progression after CAR T-cell therapy remains a major challenge, particularly in aggressive subtypes including extramedullary disease (EMD) and paramedullary disease (PMD). Real-world data on progression patterns post-CAR T cell therapy and the impact of EMD or PMD on outcomes of patients who relapsed post-CAR T-cell therapy remain scarce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this single-center, retrospective study, we evaluated progression patterns and survival outcomes in 106 MM patients who progressed after commercial CAR T-cell therapy (ide-cel or cilta-cel) between May 2021 and December 2023. Overall survival (OS) was defined from the time of post-CAR T-cell therapy progression to death or last follow-up, and progression-free survival (PFS) from post-CAR T-cell therapy progression to progression on the next line of therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Biochemical relapse occurred in 82% of patients, with EMD or PMD present in 51% at progression. Baseline EMD at the time of CAR T-cell infusion was detected in 33% of patients and was associated with significantly inferior PFS (3.6 vs. 7.0 months, p=0.0076) and OS (4.8 vs. 21.0 months, p=0.00086) compared to those without EMD. Similarly, the presence of EMD at progression was associated with shorter PFS (4.7 vs. 8.5 months, p=0.022) and OS (7.4 vs. 21.1 months, p=0.035). Patients who were EMD positive at both baseline and progression had the poorest outcomes. PMD at baseline or progression was not significantly associated with worse survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Our findings highlight that post-CAR T-cell progression in MM is heterogeneous and that EMD confers an adverse prognosis, emphasizing the critical need for imaging surveillance. Strategies such as bridging therapies aimed at reducing tumor burden prior to CAR T-cell infusion or maintenance therapies post-CAR T-cell therapy warrant further investigation to optimize responses and improve long-term survival in this high-risk population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1663814","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:19:02Z","timestamp":1761542342000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Post-progression outcomes following BCMA-directed CAR T-cell therapy in myeloma: impact of extramedullary and paramedullary disease"],"prefix":"10.3389","volume":"15","author":[{"given":"Ziad","family":"Abuhelwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fnu","family":"Amisha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyi","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"De Avila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris K.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel F.","family":"Grajales-Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Blue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Castaneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hien","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciara L.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiga","family":"Nishihori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick L.","family":"Locke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth H.","family":"Shain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachid","family":"Baz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Alsina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"B1","article-title":"Surveillance epidemiology and end results program","volume-title":"Cancer Stat Facts: Myeloma","year":""},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25415","article-title":"Progression with clinical features is associated with worse subsequent survival in multiple myeloma","volume":"94","author":"Chakraborty","year":"2019","journal-title":"Am J Hematol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41408-022-00643-3","article-title":"Extramedullary disease in multiple myeloma: a systematic literature review","volume":"12","author":"Blad\u00e9","year":"2022","journal-title":"Blood Cancer J"},{"key":"B4","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41408-022-00730-5","article-title":"Paraskeletal and extramedullary plasmacytomas in multiple myeloma at diagnosis and at first relapse: 50-years of experience from an academic institution","volume":"12","author":"Jim\u00e9nez-Segura","year":"2022","journal-title":"Blood Cancer J"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.29","article-title":"Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma","volume":"25","author":"Short","year":"2011","journal-title":"Leukemia"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.668099","article-title":"Multiple extramedullary-bone related and\/or extramedullary extraosseous are independent poor prognostic factors in patients with newly diagnosed multiple myeloma","volume":"11","author":"He","year":"2021","journal-title":"Front Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.219295","article-title":"A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome","volume":"105","author":"Beksac","year":"2020","journal-title":"Haematologica"},{"key":"B8","doi-asserted-by":"publisher","first-page":"106793","DOI":"10.1016\/j.leukres.2022.106793","article-title":"Clinical characteristics and survival outcomes of newly diagnosed multiple myeloma patients presenting with extramedullary disease: A retrospective study","volume":"115","author":"Gao","year":"2022","journal-title":"Leuk Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2281657","DOI":"10.1080\/07853890.2023.2281657","article-title":"Survival trends and prognostic factors of patients with newly diagnosed multiple myeloma accompanied with extramedullary disease","volume":"55","author":"Wang","year":"2023","journal-title":"Ann Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"New Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"New Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27469","article-title":"Clinical outcomes and microenvironment profiling in relapsed\/refractory multiple myeloma patients with extramedullary disease receiving anti-BCMA CAR T-cell-based therapy","volume":"99","author":"Qi","year":"2024","journal-title":"Am J Hematol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024965","article-title":"Tumor burden quantified by Soluble B-Cell Maturation Antigen and Metabolic Tumor Volume determine myeloma CAR-T outcomes","volume":"145","author":"Freeman","year":"2025","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","first-page":"6931","DOI":"10.3390\/ijms23136931","article-title":"CAR T cell therapy in hematological Malignancies: implications of the tumor microenvironment and biomarkers on efficacy and toxicity","volume":"23","author":"Tan","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.755866","article-title":"Anti-BCMA CAR-T cell therapy in relapsed\/refractory multiple myeloma patients with extramedullary disease: A single center analysis of two clinical trials","volume":"12","author":"Que","year":"2021","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41408-024-01190-9","article-title":"Integration of clinical outcomes and molecular features in extramedullary disease in multiple myeloma","volume":"14","author":"Nakamoto-Matsubara","year":"2024","journal-title":"Blood Cancer J"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024965","article-title":"Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determines myeloma CAR-T outcomes","volume":"145","author":"Freeman","year":"2025","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024582","article-title":"Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses","volume":"144","author":"Ailawadhi","year":"2024","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti\u2013B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41408-024-01068-w","article-title":"Impact of extraosseous extramedullary disease on outcomes of patients with relapsed-refractory multiple myeloma receiving standard-of-care chimeric antigen receptor T-cell therapy","volume":"14","author":"Dima","year":"2024","journal-title":"Blood Cancer J"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.04.002","article-title":"Extramedullary disease in multiple myeloma - controversies and future directions","volume":"36","author":"Sevcikova","year":"2019","journal-title":"Blood Rev"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0308","article-title":"The safety of bridging radiation with anti-BCMA CAR T-cell therapy for multiple myeloma","volume":"27","author":"Manjunath","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26486","article-title":"Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma","volume":"97","author":"Shi","year":"2022","journal-title":"Am J Hematol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00512","article-title":"Chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma: moving into the future","volume":"41","author":"Holstein","year":"2023","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1101495","article-title":"CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1663814\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:19:02Z","timestamp":1761542342000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1663814\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":29,"alternative-id":["10.3389\/fonc.2025.1663814"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1663814","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"article-number":"1663814"}}